
Keywords: لوپرولید; prostatic neoplasms; testosterone; prostate-specific antigen; leuprolide; mortality; ADT; androgen deprivation therapy; CAD; continuous androgen deprivation; CRPC; castration resistant prostate cancer; CSS; cause specific survival; IAD; intermittent andro